

**产品名称: YK-4-279**

**产品别名: CS-0667**

**生物活性:**

<b>Description</b>	YK 4-279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transcription factor EWS-FLI1. YK-4-279 inhibits Ewing's sarcoma family tumor (ESFT) cell growth; YK-4-279 induces apoptosis. IC50 value: Target: RNA Helicase A ES-FLI1 is an oncogenic fusion protein found in Ewing's sarcoma, a family of undifferentiated tumors that occur throughout the body. The binding of RNA helicase A (RHA) to ES-FLI1 promotes its oncogenic function. YK-4-279 is an inhibitor of protein-protein interactions between ES-FLI1 and RHA. At 10 $\mu$ M, YK-4-279 blocks RHA binding to ES-FLI1 and induces apoptosis of a panel of Ewing's sarcoma tumor cell lines with IC50 values ranging from 0.5-2 $\mu$ M. At 1.5 mg per dose, YK-4-279 reduces the growth of Ewing's sarcoma orthotopic xenografts in mice after treatment with the inhibitor for two weeks.																						
<b>Solvent&amp;Solubility</b>	<p><b>In Vitro:</b></p> <p>DMSO : 25 mg/mL (68.27 mM; Need ultrasonic)</p> <table border="1"><thead><tr><th></th><th>Solvent Concentration</th><th>Mass</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td rowspan="4">Preparing Stock Solutions</td><td>1 mM</td><td></td><td>2.7307 mL</td><td>13.6537 mL</td><td>27.3075 mL</td></tr><tr><td>5 mM</td><td></td><td>0.5461 mL</td><td>2.7307 mL</td><td>5.4615 mL</td></tr><tr><td>10 mM</td><td></td><td>0.2731 mL</td><td>1.3654 mL</td><td>2.7307 mL</td></tr></tbody></table>		Solvent Concentration	Mass	1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM		2.7307 mL	13.6537 mL	27.3075 mL	5 mM		0.5461 mL	2.7307 mL	5.4615 mL	10 mM		0.2731 mL	1.3654 mL	2.7307 mL
	Solvent Concentration	Mass	1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM		2.7307 mL	13.6537 mL	27.3075 mL																		
	5 mM		0.5461 mL	2.7307 mL	5.4615 mL																		
	10 mM		0.2731 mL	1.3654 mL	2.7307 mL																		
	<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1. 请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (6.83 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 400 <math>\mu</math>L PEG300 中，混合均匀。向上述体系中加入 50 <math>\mu</math>L Tween-80，混合均匀；然后继续加入 450 <math>\mu</math>L 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)</p> <p>Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (6.83 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 20% 的 SBE-β-CD 生理盐水溶液中，混合均匀。</p> <p>3. 请依序添加每种溶剂： 10% DMSO → 90% corn oil</p> <p>Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution</p>																						

	<p>此方案可获得 <math>\geq 2.5 \text{ mg/mL}</math> (6.83 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu\text{L}</math> 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu\text{L}</math> 玉米油中，混合均匀。</p>
<b>References</b>	<p>[1]. Barber-Rotenberg JS, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. <i>Oncotarget</i>. 2012 Feb;3(2):172-82.</p> <p>[2]. Rahim S, et al. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. <i>PLoS One</i>. 2011 Apr 29;6(4):e19343.</p> <p>[3]. Erkizan HV, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. <i>Nat Med</i>. 2009 Jul;15(7):750-6.</p>



# 源叶生物